We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more
U.S. index futures fell in pre-market trading on Thursday, particularly technology stocks, which saw a significant depreciation after Meta Platforms (NASDAQ:META) announced disheartening...
Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange...
Apple (NASDAQ:AAPL) – Smartphone shipments from Apple in China fell 19% in the first quarter due to competition from Huawei. Its market share decreased to 15.7%, nearly matching that of...
Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale...
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting...
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients...
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety...
Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin...
Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social...
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.29 | -6.86274509804 | 47.94 | 49.56 | 44.37 | 10869829 | 48.823512 | CS |
4 | -8.74 | -16.3701067616 | 53.39 | 54.475 | 44.37 | 11069328 | 50.19529351 | CS |
12 | -4.21 | -8.61645517806 | 48.86 | 55.035 | 44.37 | 15544520 | 50.99906261 | CS |
26 | -11.37 | -20.2963227419 | 56.02 | 56.77 | 44.37 | 15483656 | 50.91386853 | CS |
52 | -26.03 | -36.8279569892 | 70.68 | 70.935 | 44.37 | 12734367 | 55.25570185 | CS |
156 | -21.35 | -32.3484848485 | 66 | 81.435 | 44.37 | 11513311 | 63.85877843 | CS |
260 | -0.4 | -0.887902330744 | 45.05 | 81.435 | 41.19 | 12268620 | 61.00316173 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions